A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
Phase 2 Completed
46 enrolled
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
Phase 2 Completed
70 enrolled 11 charts
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Phase 2 Completed
27 enrolled 16 charts
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
44 enrolled 7 charts
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
Phase 2 Completed
51 enrolled
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2 Completed
60 enrolled
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Phase 1/2 Completed
60 enrolled 12 charts
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
30 enrolled
ZD1839 (IRESSAâ„¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
Phase 2 Completed
36 enrolled
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Phase 2 Completed
50 enrolled
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
Phase 1 Completed
10 enrolled
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
Phase 2 Completed
47 enrolled
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
Phase 2 Completed
64 enrolled
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Phase 2 Completed
60 enrolled
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
Phase 1/2 Completed
40 enrolled